Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido)
- PMID: 17048032
- DOI: 10.1007/s00345-006-0120-0
Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido)
Abstract
Recently, testosterone undecanoate (TU), a new parenteral testosterone (T) preparation has been introduced. Two of its distinctive features are (a) its prolonged action: after two initial loading injections 6 weeks apart, usually only one injection every 12 weeks is needed (b) over the full interval between two injections, plasma T levels are in the physiological range. New research presents convincing evidence that T has profound effects on tissues of the penis involved in the mechanism of erection and that testosterone deficiency impairs the anatomical and physiological substrate of erectile capacity, which is, at least, in part reversible upon androgen therapy. Our studies with TU demonstrated that venous leakage could be corrected with T treatment in a number of patients. We further could show that sexual functions, in a substantial number of elderly men, can be restored with treatment with T only. So, these results argue for determination of T levels in elderly men with sexual problems. If the levels are subnormal, T treatment is warranted.
Similar articles
-
The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.J Sex Med. 2010 Jun;7(6):2253-2260. doi: 10.1111/j.1743-6109.2010.01765.x. Epub 2010 Mar 15. J Sex Med. 2010. PMID: 20345732 Clinical Trial.
-
More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.Asian J Androl. 2007 May;9(3):291-7. doi: 10.1111/j.1745-7262.2007.00275.x. Asian J Androl. 2007. PMID: 17486268 Review.
-
Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone.Andrologia. 2011 Oct;43(5):293-6. doi: 10.1111/j.1439-0272.2009.00991.x. Epub 2011 Sep 15. Andrologia. 2011. PMID: 21919947 Clinical Trial.
-
Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes.J Urol. 1997 Mar;157(3):849-54. doi: 10.1016/s0022-5347(01)65062-6. J Urol. 1997. PMID: 9072584 Clinical Trial.
-
Androgen deficiency in the etiology and treatment of erectile dysfunction.Urol Clin North Am. 2005 Nov;32(4):457-68, vi-vii. doi: 10.1016/j.ucl.2005.08.002. Urol Clin North Am. 2005. PMID: 16291037 Review.
Cited by
-
Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights.Drug Healthc Patient Saf. 2023 Mar 31;15:73-84. doi: 10.2147/DHPS.S383130. eCollection 2023. Drug Healthc Patient Saf. 2023. PMID: 37025099 Free PMC article. Review.
-
Correlation between serum total testosterone and the AMS and IIEF questionnaires in patients with erectile dysfunction with testosterone deficiency syndrome.Korean J Urol. 2011 Jun;52(6):416-20. doi: 10.4111/kju.2011.52.6.416. Epub 2011 Jun 17. Korean J Urol. 2011. PMID: 21750754 Free PMC article.
-
Testosterone depot injection in male hypogonadism: a critical appraisal.Clin Interv Aging. 2007;2(4):577-90. Clin Interv Aging. 2007. PMID: 18225458 Free PMC article. Review.
-
The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial.Trials. 2020 Jun 29;21(1):591. doi: 10.1186/s13063-020-04517-6. Trials. 2020. PMID: 32600454 Free PMC article.
-
Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism.Arab J Urol. 2016 Mar;14(1):31-6. doi: 10.1016/j.aju.2015.10.002. Epub 2015 Nov 27. Arab J Urol. 2016. PMID: 26966591 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical